The effect of a monoclonal antibody to calcitonin-gene related peptide (CGRP) on injury-induced ectopic discharge following lingual nerve injury

Bowler, K.E.; Worsley, Matthew A.; Broad, Lisa M.; Sher, Emmanuel; Benschop, Robert J.; Johnson, Kirk W.; Boissonade, Fiona M.; Robinson, P.P.; Yates, Julian

doi:10.1016/j.neulet.2011.09.072

Cited by 3 publications

(2 citation statements)

References 15 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein kinases, CGRP, and Nav1.7 have been investigated as potential targets; however, only cytokine- and NGF-directed monoclonal antibodies have reached clinical trials. 6 , 77 , 78 To date, the systematic study of anti-NGF monoclonal antibodies in humans has yielded a mixed efficacy and safety record, and long-term follow-up studies are lacking, particularly in chronic disease indications. Even if anti-NGF monoclonal antibody-based treatments gain FDA clearance, the high costs of the therapy may outweigh its potential clinical value over existing treatment options.…”

Section: Discussionmentioning

confidence: 99%

Anti-nerve growth factor in pain management: current evidence

Chang

Hsu

Hottinger

et al. 2016

JPR

View full text Add to dashboard Cite

There continues to be an unmet need for safe and effective pain medications. Opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) dominate the clinical landscape despite limited effectiveness and considerable side-effect profiles. Although significant advancements have identified myriad potential pain targets over the past several decades, the majority of new pain pharmacotherapies have failed to come to market. The discovery of nerve growth factor (NGF) and its interaction with tropomyosin receptor kinase A (trkA) have been well characterized as important mediators of pain initiation and maintenance, and pharmacotherapies targeting this pathway have the potential to be considered promising methods in the treatment of a variety of nociceptive and neuropathic pain conditions. Several methodologic approaches, including sequestration of free NGF, prevention of NGF binding and trkA activation, and inhibition of trkA function, have been investigated in the development of new pharmacotherapies. Among these, NGF-sequestering antibodies have exhibited the most promise in clinical trials. However, in 2010, reports of rapid joint destruction leading to joint replacement prompted the US Food and Drug Administration (FDA) to place a hold on all clinical trials involving anti-NGF antibodies. Although the FDA has since lifted this hold and a number of new trials are under way, the long-term efficacy and safety profile of anti-NGF antibodies are yet to be established.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-nerve growth factor in pain management: current evidence

Chang

Hsu

Hottinger

et al. 2016

JPR

View full text Add to dashboard Cite

show abstract

“…There is also evidence that CGRP may contribute to the development of ectopic activity and neuropathic pain symptoms in the trigeminal system (Loescher et al, 2001;Bird et al, 2003). However, recent work from this laboratory demonstrates that the inhibition of CGRP does not affect the level of ectopic activity at sites of nerve injury (Bowler et al, 2011). The mechanism by which antibody treatment might reduce activity in the trigeminal nucleus in response to stimulation of the inflamed pulp is not yet clear.…”

Section: Discussionmentioning

confidence: 98%